Chemical compound
 ;templatestyles src="Infobox drug/styles.css"/ ;
25H-NBOMe (NBOMe-2C-H) is a derivative of the phenethylamine hallucinogen 2C-H, which acts as a highly potent full agonist for the human 5-HT2A receptor.
Pharmacology.
25H-NBOMe acts as an agonist of the serotonin 5-HT2 receptors. In accordance with its psychedelic effects in humans, it produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. The drug has also been found to produce antidepressant-like effects in rodents.
25H-NBOMe has shown reinforcing effects in rodents. This included conditioned place preference (CPP) and self-administration.
Legality.
Sweden.
The Riksdag added 25H-NBOMe to under "swedish schedule I" ("substances, plant materials and fungi which normally do not have medical use") as of August 1, 2013, published by Medical Products Agency (MPA) in regulation "LVFS 2013:15" listed as 25H-NBOMe, and 2-(2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin.
United Kingdom.
This substance is a Class A drug in the United Kingdom as a result of the "N"-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.
References.
 ;templatestyles src="Reflist/styles.css" / ;